H2APEX Group SCA Registered Shs Aktie 10989086 / LU0472835155
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
|
04.02.2026 08:00:04
|
EQS-News: H2APEX advances project development for large-scale “WAL Hydrogen from Lubmin” through PMC contract
|
EQS-News: H2APEX Group SCA
/ Key word(s): Miscellaneous
H2APEX advances project development for large-scale “WAL Hydrogen from Lubmin” through PMC contract
Laage, February 4, 2026 – H2APEX Energy GmbH is continuing project development for the European large-scale hydrogen project “WAL – Hydrogen from Lubmin” under a PMC contract. H2APEX thus strengthens its own planning security for the current financial year 2026. GHS2, the project company for the major European hydrogen project ‘WAL – Hydrogen from Lubmin’, consolidates the project-relevant assets and acts as the central governance entity for implementing the WAL project. The ownership partnership between H2APEX and CIP, successfully completed last year, forms the foundation of this structure and establishes clear responsibilities regarding asset ownership, project management, and capital allocation. The awarding of the PMC package follows the positive assessment of previous project milestones and aims to further accelerate the realization of the 100 MW IPCEI project while increasing transparency in scheduling, cost control, and operational management. “We are pleased that, through the PMC package with GHS2, we can further demonstrate to our stakeholders and investors our strategic focus on the development of hydrogen projects. It confirms the operational performance capabilities of our company and strengthens our position in the continued expansion of the WAL project,” says Peter Rössner, Managing Director of H2APEX Energy GmbH.
About H2APEX The operational core of H2APEX was founded in Mecklenburg-Western Pomerania in 2000 and has focused entirely on clean hydrogen production, storage and distribution since 2012. This makes the company one of the pioneers in this field. H2APEX's goal is to become an internationally established developer and operator of hydrogen plants. In its core business, H2APEX develops, builds and sells or operates green hydrogen plants with an electrolysis capacity of up to 2 GW. These are used to decarbonise industrial value chains and produce green hydrogen. They are used, for example, in the steel, chemical and cement industries, as well as other energy-intensive industries. In addition, the company offers systems for infrastructure and logistics, particularly for industrial use in warehouses, ports and production facilities.
H2APEX
IR.on AG
04.02.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | H2APEX Group SCA |
| 19, rue de Flaxweiler | |
| 6776 Grevenmacher | |
| Luxemburg | |
| Phone: | +352 2838 4720 |
| Fax: | +352 2838 4729 |
| E-mail: | info@h2apex.com |
| Internet: | www.h2apex.com |
| ISIN: | LU0472835155 |
| WKN: | A0YF5P |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2270858 |
| End of News | EQS News Service |
|
|
2270858 04.02.2026 CET/CEST
Nachrichten zu H2APEX Group SCA Registered Shs
Analysen zu H2APEX Group SCA Registered Shs
Longevity = mehr Rendite? Dr. Anna Erat über Healthspan & Investments – zu Gast im BX Morningcall
Im neuesten BX Morningcall ist Dr. Anna Erat zu Gast – Spezialistin für Innere Medizin, Sportmedizin, Prävention und Longevity. Gemeinsam mit Olivia Hähnel und François Bloch sprechen wir darüber, was Longevity wirklich bedeutet (Healthspan vs. Lifespan), warum es mehr ist als Biohacking und wie man seriöse Angebote von Hype unterscheidet.
Dr. Erat gibt Einblick, wie eine erste Longevity-Konsultation abläuft, welche Rolle Anamnese, Genetik/Epigenetik und Technologie/AI spielen und worauf Patientinnen und Patienten bei der Wahl eines Anbieters achten sollten. Ausserdem: Versicherung & Kostenübernahme in der Schweiz, Erwartungsdruck bei High-Performance-Klienten und ein spannender Case: Wie würde sie mit Lindsey Vonn nach einer Verletzung umgehen?
https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Heimische Zahlenflut und anstehende NVIDIA-Bilanz: SMI stabil -- DAX überspringt 25'000 Punkte -- US-Börsen fester -- KI-Hoffnungen trieben Asiens Börsen - Nikkei mit RekordSMI-Anleger halten zur Wochenmitte die Füsse still. Am deutschen Aktienmarkt sind unterdessen moderate Gewinne zu sehen. Die Wall Street notiert in Grün. An den Börsen in Asien dominierten am Mittwoch die Bullen.


